AU5053799A - Use of glucose uptake enhancer for reducing apoptosis - Google Patents

Use of glucose uptake enhancer for reducing apoptosis Download PDF

Info

Publication number
AU5053799A
AU5053799A AU50537/99A AU5053799A AU5053799A AU 5053799 A AU5053799 A AU 5053799A AU 50537/99 A AU50537/99 A AU 50537/99A AU 5053799 A AU5053799 A AU 5053799A AU 5053799 A AU5053799 A AU 5053799A
Authority
AU
Australia
Prior art keywords
glucose uptake
human
pharmaceutically acceptable
uptake enhancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50537/99A
Other languages
English (en)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Laboratoires Pharmaceutiques
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Laboratoires Pharmaceutiques
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by SmithKline Beecham Laboratoires Pharmaceutiques, SmithKline Beecham Ltd filed Critical SmithKline Beecham Laboratoires Pharmaceutiques
Publication of AU5053799A publication Critical patent/AU5053799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU50537/99A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis Abandoned AU5053799A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9815872 1998-07-21
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GB9815871 1998-07-21
GB9905387 1999-03-09
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU27684/02A Division AU2768402A (en) 1998-07-21 2002-03-26 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
AU5053799A true AU5053799A (en) 2000-02-14

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50537/99A Abandoned AU5053799A (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Country Status (25)

Country Link
EP (2) EP1516617A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002521326A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20010079551A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1310620A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2001002036A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE288746T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU5053799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG105250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9912117A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2338211A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69923687T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1098639T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA200100165A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2237929T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0103199A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID26986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL140664A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20010292L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11579A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL345627A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1098639E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK1012001A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200100207T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000004890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998010760A1 (fr) * 1996-09-12 1998-03-19 Sankyo Company, Limited Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
ATE325607T1 (de) * 1997-11-19 2006-06-15 Takeda Pharmaceutical Aptoptoseinhibitoren
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
EP1516617A2 (en) 2005-03-23
TR200100207T2 (tr) 2001-05-21
HUP0103199A2 (hu) 2002-05-29
DE69923687D1 (de) 2005-03-17
NO20010292D0 (no) 2001-01-18
BR9912117A (pt) 2001-04-10
NO20010292L (no) 2001-03-08
SK1012001A3 (en) 2001-08-06
DE69923687T2 (de) 2006-04-06
ID26986A (id) 2001-02-22
PT1098639E (pt) 2005-06-30
EP1098639B1 (en) 2005-02-09
BG105250A (en) 2001-11-30
EA200100165A1 (ru) 2001-08-27
ES2237929T3 (es) 2005-08-01
AP2001002036A0 (en) 2001-03-31
SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-08-31
ATE288746T1 (de) 2005-02-15
EP1098639A1 (en) 2001-05-16
OA11579A (en) 2004-06-01
PL345627A1 (en) 2002-01-02
DK1098639T3 (da) 2005-06-13
IL140664A0 (en) 2002-02-10
CN1310620A (zh) 2001-08-29
CA2338211A1 (en) 2000-02-03
JP2002521326A (ja) 2002-07-16
WO2000004890A1 (en) 2000-02-03
HK1037865A1 (en) 2002-02-22
HUP0103199A3 (en) 2002-08-28
KR20010079551A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
US6613785B2 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1523980A2 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1098639B1 (en) Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells
US20020099082A1 (en) Use of glucose uptake enhancer for reducing apoptosis
ZA200100438B (en) Use of glucose uptake enhancer for reducing apoptosis.
AU2768402A (en) Use of glucose uptake enhancer for reducing apoptosis
AU2005202209A1 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
HK1037865B (en) Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells
US20020082284A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
CZ20001298A3 (cs) Léčivo pro léčení hyperglykémie a farmaceutický prostředek s obsahem sensitizéru inzulinu
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AU4586902A (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted